Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Assets: 2021-2025

Historic Other Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $2.9 million.

  • ARS Pharmaceuticals' Other Non-Current Assets rose 674.01% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 674.01%. This contributed to the annual value of $3.1 million for FY2024, which is 388.09% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Other Non-Current Assets of $2.9 million as of Q3 2025, which was down 4.36% from $3.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $3.2 million during Q3 2023, with a 5-year trough of $23,000 in Q4 2021.
  • In the last 3 years, ARS Pharmaceuticals' Other Non-Current Assets had a median value of $2.9 million in 2023 and averaged $2.1 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Other Non-Current Assets soared by 12,773.91% in 2022, and later crashed by 88.12% in 2024.
  • ARS Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $23,000 in 2021, then surged by 12,773.91% to $3.0 million in 2022, then plummeted by 78.45% to $638,000 in 2023, then soared by 388.09% to $3.1 million in 2024, then spiked by 674.01% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.1 million for Q2 2025, and $3.1 million during Q1 2025.